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Abstract
Background: The aim of the study was to assess clinical and classic echocardiographic data
in patients with different cardiac resynchronization therapy (CRT) outcomes.
Methods: Sixty consecutive patients (aged 66.3 ± 8.7 years, 57 men) with chronic heart
failure (CHF) in New York Heart Association (NYHA) classes III–IV despite optimized phar-
macotherapy, with left ventricular end-diastolic diameter (LVEDD) > 55 mm, left ventricular
ejection fraction £ 35% and wide QRS complex (≥ 120 ms), including individuals with
permanent atrial fibrillation (AF) and single- and dual-chamber pacing, were assessed firstly
before, and secondly three months after, biventricular heart stimulator implantation (exclud-
ing three patients who died during the follow-up). Patients developing ≥ 10% reduction of left
ventricular end-systolic volume (LVESV) were classified as responders to CRT.
Results: The group of responders (n = 34, 59.7%) and the group of non-responders (n = 23,
40.3%) did not differ regarding baseline echocardiographic parameters or in terms of clinical
data of age, gender, concomitant diseases, smoking or pharmacological treatment. The differ-
ences involved higher rates of ischemic CHF background, prevalence of hypertension and
permanent AF, and a higher concentration of N-terminal pro-B-type natriuretic peptide (NT-
-proBNP) among the non-responders. In the multivariate logistic regression analysis, NT-proBNP,
body mass index (BMI) and the presence of permanent AF correlated negatively with the
magnitude of LVESV reduction following CRT introduction.
Conclusions: Classic echocardiographic data did not predict left ventricle reverse remodeling.
Higher rates of ischemic CHF aetiology, hypertension, permanent AF and higher NT-proBNP
concentration were found in the group without at least 10% LVESV reduction at the three
month follow-up. NT-proBNP, BMI and the presence of permanent AF had negative effects on
the magnitude of LVESV. (Cardiol J 2011; 18, 2: 157–164)
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Introduction
Cardiac resynchronization therapy (CRT) is
well-established as an effective means of managing
patients with drug-refractory chronic heart failure
(CHF) [1]. Nonetheless, despite the clinical advan-
tages of improved physical capacity and quality of
life, and decreased morbidity and mortality related
to CHF elicited by CRT, a marked percentage of
individuals do not benefit from this novel therapy
[2]. Various studies conducted in the past decade
focused mainly on the assessment of mechanical
dyssynchrony of the heart’s performance, one of the
key mechanisms of progressing CHF corrected by
CRT, thought to be the culprit for CRT failure. Re-
searchers have used many different techniques of
dyssynchrony appraisal such as echocardiographic
modalities of tissue Doppler imaging (TDI), strain,
strain rate, myocardial displacement or magnetic
resonance imaging. These studies have yielded in-
conclusive results, revealed the very often unsa-
tisfactory reproducibility of various advanced imag-
ing techniques, and showed the need for expensive
equipment and for trained and experienced staff [3–5].
The biggest disadvantage of these methods of me-
chanical dyssynchrony appraisal was their inability
to be practically applied. All the mainstream stu-
dies have been accompanied by an unrelenting in-
terest in extracting efficient information to predict
the outcome of CRT tests and examinations per-
formed in daily routine. Unfortunately, trial results
have been affected by the study inclusion criteria,
being irrelevant to patients’ heterogenous profiles
treated with CRT in clinical practice e.g. permanent
atrial fibrillation (AF) or previously implanted clas-
sic pacemaker patients.
The aim of our study was to assess the clinical
and classic echocardiographic features including
a broad array of conditions associated with poor
prognosis in CHF posted in the European Society
of Cardiology (ESC) guidelines in patients with, and
without, left ventricle reverse remodeling, follow-
ing CRT introduction [1].
Methods
Study group
Seventy two consecutive patients with chro-
nic heart failure in stable condition for at least three
months in New York Heart Association (NYHA)
classes III or IV despite optimized pharmacothe-
rapy, with left ventricle end-diastolic diameter
(LVEDD) > 55 mm, left ventricular ejection fraction
(LVEF) £ 35% and wide QRS complex (≥ 120 ms)
were enrolled in our prospective study. Eight indi-
viduals met exclusion criteria; two refused the in-
troduction of CRT; while in another two the implan-
tation of left ventricular lead did not succeed. Even-
tually, 60 patients (aged 66.3 ± ± 8.7 years, 57 men:
95%, and three women: 5%) with chronic heart fai-
lure participated in the study.
The study was approved by the local ethical com-
mittee and all patients gave their informed consent.
Exclusion criteria
Exclusion criteria comprised the presence of
unstable angina; acute myocardial infarction; coro-
nary artery bypass graft or percutaneous coronary
intervention within the previous three months; con-
tinuous or intermittent intravenous inotropic drug
therapy; an estimated life expectancy of less than
12 months; a mechanical right-side heart valve;
heart transplant; pregnancy or concurrent enrol-
ment in a study thought to confound the results.
Study design
Before CRT implantation, and at three month
follow-up (12–16 weeks), individuals were evaluat-
ed clinically as to their NYHA class, a six-minute
walk test (6-MWT), and we took a history of their
hospitalizations and used echocardiography (Ge-
neral Electric Healthcare Vivid 7; left ventricle vo-
lumes and LVEF were evaluated with biplane Sim-
pson’s method). All stored echo recordings were
analyzed off-line (Echo Pack system with GE brand
software) twice by an experienced physician with
respect to the echocardiography norms of the Eu-
ropean Association of Echocardiography (EAE) and
the recommendations of the American Society of
Echocardiography (ASE) for performance and re-
porting of echocardiographic studies for cardiac re-
synchronization therapy [3, 6]. The criteria of dia-
gnosing different clinical and biochemical disorders
were adopted from the ESC guidelines [1]. All pa-
tients undergoing CRT had had a coronarography.
An ischemic background of CHF was diagnosed
when there was at least 50% stenosis of one or more
coronary artery branches, or when a patient had
a history of coronary artery bypass graft (CABG)
or percutaneous coronary intervention (PCI) [7, 8].
Biventricular device implantation
Patients in sinus rhythm received an atrio-
biventricular stimulator (DDDR BiV: n = 47), while
those with permanent AF received a biventricular
device (VVIR BiV: n = 13). Patients with a history
of cardiac arrest and/or malignant ventricular ar-
rhythmias had a system with combined cardiover-
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ter-defibrillator (CRT-D) implanted (18 cases). Du-
ring CRT all leads were implanted transvenously.
Left ventricular lead, guided by venogram, was
placed in the coronary sinus tributary in a stable
lateral or postero-lateral position, with a < 3.5 V
capture threshold. The right ventricular lead was
placed in the septal or outflow tract (RVOT) posi-
tion. Leads’ tip positions were verified on frontal
and sagittal chest X-ray. Two patients required left
ventricular lead reposition due to their dislocation.
Atrioventricular (AV) delay remained standard pro-
grammed 150/120 ms, unless conduction of cardio-
tropic systoles was preserved. In those patients AV
was shortened until ventricles were paced (five ca-
ses). Interventricular (VV) timing left nominal
5 ms, unless no signs of biventricular stimulation in
the body surface ECG were observed. VV was
changed then to elicit the picture of QRS fusion beats
in ECG lead V1 (7 cases) as in the study of Bailey et
al. [9]. Such a VV-delay optimization was there prov-
en to correlate better with maximum rate of rise of
left ventricular pressure (dp/dtmax ) than the strategy
to obtain the narrowest paced QRS complexes [9].
In patients with permanent AF, ventricles’ rate
control with beta-blockers and digoxin was as-
sessed. In one patient, an unsatisfactory pharma-
cological effect (< 95% of biventricular stimulation)
was observed and an ablation of AV junction was
performed. The follow-up was prolonged over three
months after the ablation.
Response to CRT criterion
Patients with at least a 10% reduction of left
ventricular end-systolic volume (LVESV) after
three months of follow-up were classified as re-
sponders to CRT.
Statistical analysis
Statistical analysis was performed with SAS
System 9.1 (SAS Institute Inc., Cary, North Caroli-
na, USA) by the Student’s t-test, Fisher’s exact test
and Chi-square test. The multivariate logistic re-
gression of the association between the magnitude
of LVESV reduction and clinical variables was con-
ducted with Proc GLM. Statistical significance was
considered when p < 0.05.
Results
Clinical characteristics of the study group
In the studied group 61.6% were in sinus rhythm,
16.7% had paroxysmal AF and 21.7% permanent fi-
brillation. Conduction disorders constituted: left bun-
dle branch block 65.0%, right bundle branch block
1.7%, ventricular conduction disturbances of other
morphology 33.3%. The clinical characteristics of the
study group are summarized in Tables 1 and 2.
Course of the study
Three patients died during the three-month
follow-up: one of a stroke, one of myocardial infarc-
tion, and one suddenly at home of unknown cause.
These individuals were excluded from further ana-
lysis.  In the observation period, ten patients were
hospitalized, seven of them due to CHF exacerba-
tion. All prescriptions (medications — see Table 2)
remained stable through the study.
Effects of CRT
In the whole studied group, LVEF increased
(21.7 ± 4.8% vs 26.6 ± 4.8%, p < 0.0001), 6-MWT
distance rose (298.0 ± 107.4 m vs 373.1 ± 127.1
m, p < 0.0001), and left ventricular end-diastolic
volume (LVEDV) and LVESV decreased (244.3 ±
± 83.8 mL vs 226.4 ± 88.6 mL, p = 0.0002; 192.8 ±
± 71.9 mL vs 168.7 ± 76.5 mL, p < 0.0001, respec-
tively). Mean NYHA class dropped from 3.1 ± 0.27
to 2.2 ± 0.67 (p < 0.0001). The results of specia-
lized examinations before and after biventricular
stimulation introduction in the studied subgroups
of responders (n = 34, 59.7%) and non-responders
to CRT (n = 23, 40.3%) are shown in Table 3.
Echocardiographic parameters
and clinical end point
There was no difference regarding baseline and
follow-up echocardiographic parameters between
patients with and without left ventricle reverse re-
modeling in terms of clinical endpoint i.e. history
of hospitalization due to heart failure exacerbation
in the observation period.
Multivariate logistic regression model
In the multivariate logistic regression analysis,
having considered the parameters discriminating
responders from non-responders, the magnitude of
LVESV reduction [ml] in the whole study group
correlated significantly with body mass index (BMI)
(r2 = –4.18, p < 0.001), the level of N-Terminal
Pro-B-Type Natriuretic Peptide (NT-proBNP)
(r2 = –3.28, p = 0.002) and the presence of perma-
nent AF (r2 = –2.1, p = 0.041).
Discussion
Clinical and echocardiographic effects of CRT
Clinical trial results (MUSTIC-SR, MIRACLE,
MUSTIC-AF, PATH CHF, MIRACLE ICD, CON-
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Table 1. Clinical data of the whole study group, and of responder and non-responder subgroups,
according to the applied criterion of at least 10% left ventricular end-systolic volume reduction at
three-month follow-up (data presented as mean value with standard deviation [SD] or number of
patients with the percentage share [%] of the whole analyzed group or subgroup, p — value for
comparison between responders and non-responders).
Whole study Responders; Non-responders; P
population; n = 60 n = 34  n = 23
Age (years) 66.3 (8.7%) 65.8 (8.2%) 67.1 (9.4%) 0.60
Gender — men (%) 57 (95%) 33 (97%) 24 (92%) 0.57
Weight [kg] 74.3 (13.9%) 72.7 (12.4%) 75.6 (16.3%) 0.46
Height [cm] 168.3 (7.7%) 168.3 (7.8%) 168.2 (7.7%) 0.95
BMI [kg/m2] 26.1 (4.3%) 26.0 (3.0%) 27.0 (5.0%) 0.33
NYHA 3.1 (0.2%) 3.1 (0.3%) 3.1 (0.2%) 0.91
Ischemic etiology of CHF 43 (71%) 21 (62%) 22 (84%) 0.04
History of myocardial infarction 38 (63.3%) 20 (59%) 18 (69%) 0.43
Permanent atrial fibrillation 13 (22%) 6 (18%) 7 (27%) 0.048
History of hypertension 39 (65%) 17 (50%) 22 (84%) 0.01
Diabetes mellitus type 2 25 (42%) 12 (35%) 13 (50%) 0.30
COPD 11 (18%) 7 (21%) 4 (15%) 0.52
Hypercholesterolemia 46 (76%) 26 (76%) 20 (76%) 0.99
Hyperuricemia 17 (28%) 9 (26%) 8 (31%) 0.56
Anaemia 2 (3%) 2 (6%) 0 (0%) 0.35
Hyponatremia 13 (22%) 9 (26%) 4 (15%) 0.32
Up-grade VVI 2 (3%) 0 (0%) 2 (8%) 0.16
Up-grade DDD 9 (15%) 6 (17%) 3 (11%) 0.47
Up-grade DDD-ICD      3 (5%) 2 (6%) 1 (3%) 0.64
CRT-D 18 (30%) 11 (32%) 7 (27%) 0.56
BMI — body mass index; CHF — chronic heart failure; COPD — chronic obstructive pulmonary disease; CRT-D — cardiac resynchronization therapy
with defibrillator function; DDD — dual chamber pacemaker; DDD-ICD – dual chamber implantable cardioverter-defibrillator; NYHA — New York Heart
Association functional classification; VVI — right ventricular pacemaker
Table 2. Clinical data and drug medication of the whole study group, and of responder and non-
-responder subgroups, according to the applied criterion of at least 10% left ventricular end-systolic
volume reduction at three-month follow-up (data presented as mean value ± standard deviation [SD]
or number of patients with the percentage share [%] of the whole analyzed group or subgroup,
p — value for comparison between responders and non-responders).
Study group; Responders; Non-responders; P
n = 60  n = 34  n = 23
History of stroke 4 (6.7%) 3 (9%) 1 (3%) 0.62
Chronic renal disease 20 (33.3%) 8 (23%) 12 (46%) 0.09
Smoking 9 (15%) 6 (17%) 3 (11%) 0.71
History of smoking 14 (23.3%) 9 (26%) 5 (19%) 0.55
Hypotension 4 (7%) 0 (0%) 4 (15%) 0.02
History of hospitalization for CHF 50 (83%) 28 (82%) 20 (77%) 0.74
History of cardiac arrest 4 (7%) 2 (6%) 2 (8%) 0.53
Pulmonary rales 21 (35%) 10 (29%) 11 (42%) 0.13
Complex ventricular arrhythmias 18 (30%) 11 (32%) 7 (27%) 0.56
Q waves in an electrocardiogram 17 (28%) 10 (29%) 7 (27%) 0.58
Enlarged right ventricle 33 (55%) 18 (53%) 15 (58%) 0.64
Pulmonary hypertension 28 (47%) 16 (47%) 12 (46%) 0.79
Restrictive mitral filling pattern 13 (22%) 9 (26%) 4 (15%) 0.73
Medication: ACEI/ARB 51 (85%) 30 (88%) 21 (81%) 0.48
Beta-blocker 58 (96.7%) 33 (97%) 25 (96%) 0.99
Loop diuretic 53 (88.3%) 28 (82%) 25 (96%) 0.12
Potassium-sparing diuretic 40 (66.7%) 25 (73%) 15 (58%) 0.27
Digoxin 13 (21.7%) 8 (23%) 5 (19%) 0.76
Amiodarone 18 (30%) 9 (26%) 9 (35%) 0.39
ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin II receptor blocker; CHF — chronic heart failure
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TAK CD, MIRACLE ICD II, COMPANION, CARE
HF) show that CRT leads to reduction in NYHA
class by 0.5–0.8 points and improves physical ca-
pacity estimated via 6-MWT distance by 20% [5].
The effects of CRT regarding those parameters
were similar in our study. Also, the reduction of
LVESV rate as a sign of reversal of left ventricle
remodeling is similar to values met in the literature.
In the PROSPECT study, a more pronounced de-
crease of LVESV (≥ 15%) as an end point was not-
ed in 56.3% of participants, but the follow-up was
longer: up to six months [10].
Rationale for response
to CRT criterion choice
Despite the subjectivity of clinical and echocar-
diographic assessment and multiplicity of response
to CRT criteria, cardiac resynchronization therapy
is an efficient treatment for advanced CHF [11, 12].
Among the factors offering a positive long-term
prognosis in patients undergoing CRT, the presence
of left ventricle reverse remodeling observed a few
months after CRT introduction with at least 10%
LVESV reduction, is the best marker [13, 14].
Conditions of poor prognosis in CHF
Taking into account the effects of CRT, it
should be emphasized that decreased morbidity and
mortality related to CHF, and improved physical
capacity and quality of life observed in patients fol-
lowing biventricular heart stimulator implantation
are conditioned by numerous factors such as age,
concomitant diseases, BMI, physical activity, and
compliance. CRT is only a part of a complex CHF
treatment [1]. Some researchers also claim that
a huge proportion of this phenomenon can be attri-
buted to the placebo effect [15]. Numerous prognos-
tic factors of CRT failure have been identified in the
literature including: NYHA IV class; left ventricle
dilatation (LVEDD > 65–70 mm); low LVEF
(< 30%); the presence of scar tissue in the myocar-
dium; suboptimal left ventricular lead position; val-
vular defects with advanced mitral insufficiency; in-
adequate ventricles’ rate control in patients with per-
manent AF without AV junction ablation; lack of
initial mechanical dyssynchrony; ineffective biven-
tricular stimulation; unsuitable stimulator settings
of AV and VV delay [1, 2, 5, 16]. It is worth noting
that the optimal dyssynchrony assessment, left ven-
Table 3. Specialized examination results of responders and non-responders according to the applied
criterion of at least 10% left ventricular end-systolic volume reduction at three month follow-up. Each
parameter presented as arithmetic mean with standard deviation (SD); p — for the difference between
initial and three months follow-up values of the same parameter; #p < 0.05 — for the difference betwe-
en initial parameters of responders and non-responders; *p< 0.05 — for the difference between para-
meters of responders and non-responders measured after three months of follow-up.
Responders (n = 34, 59.7%) Non-responders (n = 23, 40.3%)
Initially After three P Initially After three P
months  months
LVEDD [mm] 73.2 (7.4) 69.9 (8.3) < 0.001 73.5 (10.9) 73.9 (11.5) 0.47
LVESD [mm] 62.0 (7.9) 58.1 (9.4) 0.003 63.0 (12.7) 64.2 (13.0)* 0.13
LVEDV [mL] 246.3 (61.1) 209.5 (58.7) < 0.001 241.3 (110.7) 251.4 (117.6) 0.054
LVESV [mL] 194.5 (55.9) 153.0 (51.4) < 0.001 190.3 (92) 191.8 (99.9) 0.68
SV [mL] 51.6 (12.8) 56.3 (12.4) 0.002 51.4 (21.3) 59.6 (22.2) 0.002
MR (%) 25.6 (14) 18.4 (11) 0.001 23.7 (11) 24.4 (11) 0.62
QRS [ms] 179 (28) 153 (20) 0.001 199 (27) 152 (17) 0.001
LVEF (%) 21.5 (4.9) 27.1 (4.8) < 0.001 21.9 (4.7) 24.5 (4.7)* 0.003
6-MWT [m] 315.7 (112.1) 392.3 (109.5) < 0.001 271.9 (96) 344.7 (147.4) 0.001
NYHA 3.1 (0.3) 2.1 (0.5) < 0.001 3.1 (0.2) 2.5 (0.8) 0.001
NT-proBNP [pg/mL] 2005.6 (1632) 1512.0 (1148) 0.012 3150.5 (2034)# 2509.5 (1403)* 0.32
SPWMD [ms] 98.9 (36) 99.2 (56) 0.86 85.5 (60.1) 62.2 (57) 0.79
IVMD [ms] 58.8 (25) 46.6 (22) 0.047 57.8 (26) 35.6 (30) 0.037
VV-sep. [cm] 8.1 (2.9) 8.9 (2.3)
6-MWT — 6-minute walk test distance; IVMD — interventricular mechanical delay; LVEDD — left ventricular end-diastolic diameter; LVEDV — left
ventricular end-diastolic volume; LVEF — left ventricular ejection fraction; LVESD — left ventricular end-systolic diameter; LVESV — left ventricular
end-systolic volume; MR — mitral regurgitation presented as percentage of left atrium area; NT-proBNP — N-terminal pro-B-type natriuretic peptide;
NYHA — New York Heart Association functional classification; SPWMD — septal to posterior wall motion delay; SV — stroke volume; VV-sep. —
right and left ventricular electrodes tips’ separation on sagittal chest X-ray
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tricular lead positioning and device programming,
despite a good deal of investigation being done into
the issues, have yet to be elaborated.
In our study, ischemic etiology of CHF, per-
manent AF, higher prevalence of hypertension and
hypotension and higher NT-proBNP concentrations
were observed in the group without ≥ 10% LVESV
reduction in the follow-up. Negative effects of NT-
-proBNP, BMI and the presence of permanent AF
on the magnitude of LVESV reduction following
CRT introduction were found in the multivariate
logistic regression model.
In the MIRACLE study, LVEF rose by less in
patients with a non-ischemic CHF background. This
has not been confirmed in other trials [17, 18]. In-
terestingly, it is the presence of scar tissue that is
thought to be of major importance here. In the study
by Jansen et al. [19] on the role of scar in the heart
muscle, 15% of patients with a diagnosed ischemic
background of CHF, based on history of CABG, PCI,
myocardial infarction and results of the coronaro-
graphy, did not have features of transmural scar in
magnetic resonance imaging (MRI); whereas in 19%
of individuals with idiopathic cardiomyopathy, such
signs were present. The negative influence of cor-
onary artery disease on the reversal of malfunction-
al left ventricle remodeling induced by biventricu-
lar stimulation seems thus also to involve aspects
other than the presence of scar. The course of hy-
pertension is associated with myocardial architec-
ture changes, which might impede CHF left ven-
tricle remodeling regression following CRT intro-
duction [20]. Hypotension is a sign of severe CHF
with a heavily damaged heart muscle, an accepted
risk factor of poor prognosis. So the fact that all four
patients with hypotension were found in the group
with no response to CRT came as no surprise [21].
Increased BMI, especially in the obese, is associ-
ated with CHF progression, more severe symptoms
and worsening of well-being. BMI in our study has
affected negatively the reverse remodeling. The
results of meta-analysis by Upadhyay et al. on 1,164
CRT recipients, released after the latest ESC guide-
lines on cardiac pacing and CRT were published, in-
dicate similar echocardiographic and clinical effects
of CRT in patients with permanent AF with phar-
macological ventricles’ rate control vs individuals
in sinus rhythm. Our findings do not comply with
those observations but are in consent with some
small trials [22–24].
Echocardiography
In our study, responders did not differ from
non-responders in respect of baseline left ventri-
cular end-diastolic and end-systolic diameters and
volumes, or the size of mitral regurgitation. Re-
sponders presented a decrease in the aforemen-
tioned parameters, while non-responders did not
show reduced LVEDD, left ventricular end-systo-
lic diameter (LVESD), LVEDV, LVESV or degree
of severity of mitral regurgitation. Interestingly, the
group with no response to CRT according to the
adopted criterion, despite lacking left ventricle re-
verse remodeling, also gained benefit from the ther-
apy. This might be explained by the fact that clini-
cal and echocardiographic responses to CRT may
not always appear simultaneously, and patients who
respond clinically may not exhibit reverse remo-
deling and vice versa [11].
Classic echocardiographic-derived
dyssynchrony parameters
Two of the simplest parameters of mechanical
dyssynchrony deriving from classic echocardio-
graphic examination techniques are septal to pos-
terior wall motion delay (SPWMD) and interventri-
cular mechanical delay (IVMD).
SPWMD (being based on measurements to the
peak of systolic wave of heart walls) suffers from
error of interaction between active and passive
movements of myocardial segments, something
emphasized by Marcus et al. [25] in the 79 partici-
pants of the CONTAK-CD trial. The PROSPECT
study revealed unsatisfactory intra- and interob-
server reproducibility of this parameter [10]. ASE
does not recommend the use of M-mode as an iso-
lated method of mechanical dyssynchrony apprais-
al, but indicates that it might provide some acces-
sory information to the results gained with other
techniques such as TDI [3].
    IVMD, although reproducible and easily cal-
culated in daily practice, has little efficacy in pre-
dicting response to CRT as compared to intraven-
tricular dyssynchrony assessment [10]. In our
study, both groups presented marked but compa-
rable inter- and intraventricular dyssynchrony as-
sessed with IVMD and SPWMD (normal values
proposed by ASE expert consensus statement are
for IVMD < 20 ms and for SPWMD < 50 ms) [3].
The index SPWMD was not altered by CRT in re-
sponders and non-responders, while biventricular
stimulation significantly improved IVMD.
Biochemical markers of CHF
Results of studies confirm that CRT improv-
ing heart function leads to a decrease of B-type
natriuretic peptide (BNP) and NT-proBNP levels.
Additionally, patients with persistently high concen-
163
Jerzy Wiliński et al., Characteristics of patients with different CRT outcomes
www.cardiologyjournal.org
trations after CRT introduction have higher all-
cause mortality in the long-term observation (data
from CARE-HF study on 813 individuals with mean
37.6 months follow-up and NT-proBNP assessment
three months after CRT implantation) [26–28]. In
our study, individuals without left ventricle reverse
remodeling had a higher concentration of NT-proBNP
initially and after the given follow-up period.
NT-proBNP decreased only in patients with reverse
remodeling, and its baseline level correlated nega-
tively with the magnitude of LVESV reduction when
the whole study group was considered. This sug-
gests that left ventricle reverse remodeling is as-
sociated with an improvement in the biochemical
parameters of CHF.
QRS complex duration
In most papers, QRS complex width did not
carry prognostic value of variously defined response
to CRT. QRS duration would not differ initially and
after certain periods of the follow-up between
groups with and without response to CRT [29, 30].
In our study, baseline QRS width diminished but we
observed no difference between initial and final
values of the analyzed groups.
Conclusions
Classic echocardiographic data do not predict
left ventricle reverse remodeling. Significantly
higher prevalence of hypertension and permanent
AF and higher NT-proBNP concentration were
found in the group without at least 10% LVESV
reduction in the three-month follow-up. NT-proBNP,
BMI and the presence of permanent AF had nega-
tive effects on the magnitude of LVESV reduction
following CRT introduction.
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